Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910